GeneDx Announces Leadership Transition
Key Highlights
- ➤Everett Cunningham appointed GeneDx CEO and board member by December 15, 2026
- ➤Katherine Stueland steps down as CEO and director after five-year transformation
- ➤GeneDx reaffirms full-year 2026 financial guidance issued November 9, 2026
- ➤Cunningham joins GeneDx after serving as Quanterix President and CEO
Expert Statements
Keith Meister, Chairman of the GeneDx Board of Directors
“Everett is one of the most accomplished commercial leaders in our industry, and he is the right person to lead GeneDx into its next phase of growth.”
Keith Meister, Chairman of the GeneDx Board of Directors
“For more than three decades, Everett has built and led high-performing commercial organizations at some of the most important companies in healthcare and is uniquely positioned to move innovative diagnostics from early adoption to standard of care as we embrace the opportunity to bring exome and genome sequencing to more clinicians and families.”
Keith Meister, Chairman of the GeneDx Board of Directors
“On behalf of the Board, I want to thank Katherine for her transformational leadership over the past five years. She led GeneDx through its combination with Sema4, delivered significant revenue growth, and helped establish GeneDx as the leader in rare disease diagnosis. We are grateful for everything she has accomplished and the lasting impact of her leadership.”
Everett Cunningham, Chief Executive Officer of GeneDx
“GeneDx has built a remarkable foundation, with unmatched clinical expertise, the world’s largest rare disease genomic dataset and a team that is deeply committed to the families it serves.”
Everett Cunningham, Chief Executive Officer of GeneDx
“I have spent my career helping bring innovative diagnostics to clinicians and patients at scale, and I believe GeneDx has a tremendous opportunity to make exome and genome sequencing the first-line standard of care.”
Everett Cunningham, Chief Executive Officer of GeneDx
“I’m excited to work with GeneDx President Mark Gardner, the leadership team and the Board to accelerate adoption, execute with discipline and deliver for patients and shareholders alike.”
Katherine Stueland, outgoing Chief Executive Officer of GeneDx
“Five and a half years ago, I joined GeneDx as CEO to lead its transformation into an independent company, grow the business, and achieve profitability. Together, we’ve delivered on all these commitments.”
Katherine Stueland, outgoing Chief Executive Officer of GeneDx
“Most of all, I’m proud of what all this work adds up to: more families getting an accurate diagnosis sooner.”
Katherine Stueland, outgoing Chief Executive Officer of GeneDx
“Part of this journey has been building an exceptional team to lead our next phase of growth, and now is a natural time for me to pass the baton.”
Katherine Stueland, outgoing Chief Executive Officer of GeneDx
“I’m delighted to welcome Everett and look forward to seeing GeneDx go from strength to strength.”
Everett Cunningham, veteran diagnostics and commercial leader, appointed Chief Executive Officer to lead next phase of growth
Katherine Stueland announces her departure from the company after successful transformation of GeneDx
Get started
Create a free account to read the full story.
